☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Exelixis
Exelixis Reports the US FDA’s sNDA Acceptance of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors
August 7, 2024
Exelixis and Sairopa Receive the US FDA’s IND Clearance for ADU-1805 to Treat Advanced Solid Tumors
February 14, 2023
Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer
January 11, 2023
Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs
November 4, 2022
Exelixis Entered into an Exclusive Clinical Development Collaboration and Option Agreement with Sairopa to Develop ADU-1805 for Ca...
November 2, 2022
Exelixis Entered into an Exclusive Collaboration Agreement with Cybrexa to Acquire CBX-12 for Solid Tumors
November 2, 2022
Load more...
Back to Home